SVRA on Nasdaq

Savara Inc

American pharmaceutical preparations company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with CytoMed Therapeutics Ltd, CytoDyn Inc. or Geron Corporation, or pick any stock.

  • TickerSVRA on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDE
  • Incorporated inDE2
  • Business address6836 Bee Cave Road, Building 3, Suite 201, Austin, Tx 787462
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-19182.9%Operating margin3
-19305.4%Net margin3
-77.1%Return on equity4
0.39×Debt to equity3
-$39.9MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Other costs100¢$257.0K

Out of $257.0K in revenue.3 The company lost money this year.

Financial statements

Revenue53$257.0K in 2020
0$100.0K$200.0K$300.0K2019: $0$020192020: $257.0K$257.0K2020
Operating income63-$49.3M in 2020−38% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$79.0M-$79.0M20192020: -$49.3M-$49.3M2020−38%
Net income63-$49.6M in 2020−37% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$78.2M-$78.2M20192020: -$49.6M-$49.6M2020−37%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$81.4M$78.0M
General and administrative$42.1M$25.0M
Depreciation and amortization$87.0K$130.0K
Total operating expenses$123.5M$103.2M
Loss from operations-$123.5M-$103.2M
Interest income, net$4.2M$6.5M
Foreign currency exchange gain$310.0K$51.0K
Tax credit income$784.0K$797.0K
Loss on extinguishment of debt-$546.0K
Total other income, net$4.7M$7.3M
Net loss-$118.8M-$95.9M
Basic-$0.53-$0.48
Diluted-$0.53-$0.48
Basic222.4M shares198.2M shares
Diluted222.4M shares198.2M shares
Gain (loss) on foreign currency translation$665.0K-$523.0K
Unrealized gain (loss) on short-term investments-$2.0K$44.0K
Total comprehensive loss-$118.2M-$96.4M

Compare Savara Inc with another company

Leadership

Who has led Savara Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Evan Levine2006–2008
  2. Brian M. Culley2010–2017
  3. Robert N. Neville2017–2019
  4. Matthew Pauls2020–now

President

  1. Evan Levine2006–2008
  2. James A. Merritt2006–2007
  3. Patrick L. Keran2010–2015
  4. Jaakko Taneli Jouhikainen2019

Chief financial officer

  1. Carrie Carlander2006
  2. Robert A. Daniel2006
  3. Gregory P. Hanson2006
  4. Mark Bagnall2008
  5. Brandi Roberts2013–2017
  6. David L. Lowrance2017–now

Chief operating officer

  1. Patrick L. Keran2010–2015
  2. Jaakko Taneli Jouhikainen2019
2010201520202025
Board members and other officers (43)

Former names

  • Mast Therapeutics, Inc.Mar 12, 2013 to Apr 25, 20172
  • ADVENTRX PHARMACEUTICALS INCAug 14, 2003 to Mar 1, 20132
  • BIOKEYS PHARMACEUTICALS INCOct 2, 2001 to May 15, 20032

Timeline

  1. Dec 17, 2020New chief executive Matthew Pauls becomes CEO10
  2. May 5, 2017New chief executive Robert N. Neville becomes CEO11
  3. Feb 3, 2010New chief executive Brian M. Culley becomes CEO12
  4. Apr 25, 2006New chief executive Evan Levine becomes CEO13

Filings

263 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 34 major events, 122 insider forms, 45 large holders, 41 other. The latest 20:

  1. Sep 25, 20264 EDGAR
  2. Aug 11, 2026S-8 EDGAR
  3. Aug 11, 202610-Q EDGAR
  4. Jul 24, 20264 EDGAR
  5. Jun 22, 2026144 EDGAR
  6. Jun 22, 20264 EDGAR
  7. Jun 8, 20268-K EDGAR
  8. May 12, 202610-Q EDGAR
  9. Apr 24, 2026ARS EDGAR
  10. Apr 24, 2026DEFA14A EDGAR
  11. Apr 24, 2026DEF 14A EDGAR
  12. Apr 10, 2026PRE 14A EDGAR
  13. Mar 20, 20264 EDGAR
  14. Mar 13, 20268-K EDGAR
  15. Mar 13, 202610-K EDGAR
  16. Feb 17, 2026SCHEDULE 13G/A EDGAR
  17. Feb 17, 20264 EDGAR
  18. Feb 17, 2026SCHEDULE 13G/A EDGAR
  19. Feb 13, 2026SCHEDULE 13G/A EDGAR
  20. Feb 13, 2026SCHEDULE 13G/A EDGAR

The 263 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 45 such filings since October 2021, the latest 10:

  1. Feb 17, 2026SCHEDULE 13G/A
  2. Feb 17, 2026SCHEDULE 13G/A
  3. Feb 13, 2026SCHEDULE 13G/A
  4. Feb 13, 2026SCHEDULE 13G/A
  5. Feb 5, 2026SCHEDULE 13G/A
  6. Jan 21, 2026SCHEDULE 13G
  7. Nov 14, 2025SCHEDULE 13G/A
  8. Nov 14, 2025SCHEDULE 13G
  9. Nov 14, 2025SCHEDULE 13D/A
  10. Nov 14, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
NEA Management Company, LLC24,471,264$150.7M9.5%No change
Bain Capital Life Sciences Investors, LLC17,600,621$108.4M6.4%No change
Venrock Adviser, LLC14,745,943$90.8M2.8%+1,005,568
Nantahala Capital Management, LLC13,953,620$86.0M2.6%+6,608,837
Deerfield Management Company, L.P.13,569,000$83.6M1.0%No change
BlackRock, Inc.12,494,498$77.0M0.0%+1,203,313
TCG Crossover Management, LLC12,362,205$76.2M1.8%No change
Frazier Life Sciences Management, L.P.9,720,852$59.9M1.3%No change
Polar Capital Holdings Plc9,541,786$58.8M0.2%No change
Vanguard Capital Management LLC7,932,545$48.9M0.0%+148,632
State Street Corp6,553,348$40.4M0.0%−154,336
Marshall Wace, Llp6,256,989$38.5M0.0%+1,742,641
Rtw Investments, LP5,952,380$36.7M0.3%No change
Woodline Partners LP4,245,119$26.1M0.1%No change
Orbimed Advisors LLC3,959,900$24.4M0.5%+3,324,900
Geode Capital Management, LLC3,872,133$23.9M0.0%+277,653
Spruce Street Capital LP3,452,576$21.3M4.2%+69,401
Rosalind Advisors, Inc.3,178,121$19.6M7.4%−25,600
Emerald Advisers, LLC3,148,439$19.4M0.5%−222,846
Pictet Asset Management Holding SA2,763,055$17.0M0.0%+487,674
Vestal Point Capital, LP2,720,000$16.8M0.4%+119,948
Wellington Management Group Llp2,694,812$16.6M0.0%−15,911
D. E. Shaw & Co., Inc.2,514,998$15.5M0.0%+403,116
Affinity Asset Advisors, LLC2,512,153$15.5M0.8%No change
Emerald Mutual Fund Advisers Trust2,375,999$14.6M0.5%+7,330

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63